Journal of Food Protection Publishes Two Articles on E. coli O157:H7 Vaccine Efficacy

    - articles published in November, 2007 issue -

    BELLEVILLE, ON, Nov. 13 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, today
announced that two articles have been published in a peer-reviewed journal,
the Journal of Food Protection, both in regards to the efficacy of the
Company's E. coli O157:H7 cattle vaccine. The two articles relate to field
challenge studies conducted at the University of Nebraska-Lincoln involving
close to 900 animals in 2002 and 2003.
    The first article, "Efficacy of dose regimen and observation of herd
immunity from a vaccine against Escherichia coli O157:H7 for feedlot cattle"
(R.E. Peterson, T.J. Klopfenstein, R.A. Moxley, G.E. Erickson, S. Hinkley, D.
Rogan, and D.R. Smith), supports the hypothesis that use of the Bioniche
vaccine effectively reduces the likelihood of cattle shedding E. coli O157:H7.
After a three-dose treatment, vaccinated cattle were significantly less
likely (73%) to shed the organism than unvaccinated cattle (P(less
than)0.0001). The same study noted that there was no indication of affect on
(feed conversion) performance or carcass quality, and that vaccinating a
majority of cattle within a pen resulted in a significant protective effect to
unvaccinated cattle in the same pen. This effect is called "herd immunity".
    The second article, "Effect of a vaccine product containing type III
secreted proteins on the probability of Escherichia coli O157:H7 fecal
shedding and mucosal colonization in feedlot cattle" (R.E. Peterson, T.J.
Klopfenstein, R.A. Moxley, G.E. Erickson, S. Hinkley, G. Bretschneider, E.M.
Berberov, D. Rogan, and D. R. Smith), highlights the results of a study that
looked at the effect of vaccination on the shedding of E. coli O157:H7 by
cattle and their colonization by the organism. Vaccinated cattle were
98.3% less likely to be colonized by E. coli O157:H7 at the terminal rectum
(where the bacteria are known to collect and reproduce in large quantities).
Specifically, the authors were able to isolate E. coli O157:H7 from only one
of 140 vaccinated cattle, versus 38 of 141 non-vaccinates (P(less
    "These two peer-reviewed journal publications substantiate the efficacy
of the Bioniche vaccine," said Dr. Dragan Rogan, Vice-President, Animal Health
Research & Development at Bioniche Life Sciences Inc. "Not only has the
vaccine substantially reduced the amount of E. coli O157:H7 shed by cattle
into the environment, it has reduced the likelihood that cattle are colonized
by the organism, thus reducing the reproduction of new bacteria and thereby
lowering overall bacterial load in a feedlot environment."
    It remains very clear that there is a pressing need to reduce the amount
of E. coli O157:H7 shed into the environment by cattle. Food recalls continue
to occur on a massive scale in beef, produce and prepared food: Just from
September, E. coli O157:H7-related recalls have totalled 22.7 million pounds
of beef, packaged greens and five million frozen pizzas. Pre-harvest
interventions to reduce the shedding of E. coli O157:H7 by cattle, such as
vaccination, may assist in reducing the potential for food and water
contamination and the resulting human illnesses and deaths.

    About the Journal of Food Protection

    The Journal of Food Protection provides up-to-date, original research
reports in food science and technology. First published in 1937, the Journal
of Food Protection is a refereed monthly publication. Each issue contains
scientific research and authoritative review articles reporting on a variety
of topics in food science pertaining to food safety and quality. The journal
is internationally recognized as the leading publication in the field of food
microbiology with a readership exceeding 11,000 scientists from 69 countries.
The Journal of Food Protection is indexed in Index Medicus, Current Contents,
BIOSIS, PubMed, Medline, and many others. The journal can be found on-line at

    About E. coli O157:H7

    Escherichia coli (E. coli) bacteria are normal organisms found in the
intestinal tract of all animals and humans. Most E. coli are non-pathogenic
(non-disease-causing) to their host. However certain strains can cause
intestinal disease and, occasionally, other significant systemic disease. The
E. coli O157:H7 bacterium, which was first identified in South America in the
late 1970s and drifted northward, produces a powerful toxin (shiga/vero toxin)
that can cause severe illness in humans and often result from consumption of
contaminated food or water.
    Today, the bacteria can be found in most cattle herds in North America,
South America, Europe and Asia. Ruminant livestock (e.g. cattle) are
considered the major reservoir of E. coli O157:H7 worldwide. Numerous studies
have demonstrated that the incidence of E. coli O157:H7 in beef and dairy
cattle is widespread and that the organism is found in, on, and around cattle
in all parts of the world. Use of manure as fertilizer for crop production and
run-off from beef and dairy cattle operations are a source of contamination
for the general environment, as well as surface and ground water. E. coli
O157:H7 contamination of food and water as a result of fecal shedding by
livestock is a well-recognized and documented threat to human health.

    About E. coli O157:H7 Infection

    The U.S. Centers for Disease Control estimates that E. coli O157:H7
infection affects some 73,000 people per year in the United States, and that
2% to 7% of those people develop hemolytic uremic syndrome (HUS), a disease
characterized by kidney failure (in recent outbreaks, this percentage has
risen to as high as 16%). Five percent of HUS patients die, many of them
children and senior citizens, whose kidneys are more sensitive to damage. The
annual cost in the United States is estimated at more than $650 million due to
medical expenses, lost productivity and death.

    About the E. coli O157:H7 Cattle Vaccine

    This vaccine received international recognition in September, 2007 by the
Animal Pharm Industry Excellence Awards as the best new veterinary product for
livestock. The vaccine has been developed by a strategic alliance formed in
2000 between the University of British Columbia (UBC), the Alberta Research
Council (ARC), the University of Saskatchewan's Vaccine & Infectious Disease
Organization (VIDO), and Bioniche, which holds the rights for worldwide
commercialization of the vaccine. The vaccine prevents the E. coli O157:H7
bacteria from attaching to the intestines of vaccinated cattle, thereby
reducing their reproduction within the animal, and reducing the amount of
bacteria that can be released through cattle manure in the environment. More
than 30,000 cattle have been involved in clinical testing of the vaccine over
the past five years.

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
195 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. For more information, please visit

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00013159EF

For further information:

For further information: Jennifer Shea, Corporate Communications &
Investor Relations Manager, Bioniche Life Sciences Inc., Telephone: (613)
966-8058, Cell: (613) 391-2097,

Organization Profile

Telesta Therapeutics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890